RECENT APPROACHES FOR SODIUM-GLUCOSE CO-TRANSPORTER 2 INHIBITORS IN THE MANAGEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE | ||
Bulletin of Pharmaceutical Sciences Assiut University | ||
Volume 46, Issue 1, June 2023, Pages 579-595 PDF (1.18 M) | ||
Document Type: Original Article | ||
DOI: 10.21608/bfsa.2023.301257 | ||
Authors | ||
Gehan H. Heeba* 1; Mohamed Y. Abolnaga2; Eman M. Othman2 | ||
1Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, El-Minia, Egypt | ||
2Department of Biochemistry, Faculty of Pharmacy, Minia University, El-Minia, Egypt | ||
Abstract | ||
NAFLD is an umbrella term for a variety of illnesses of ranging severity starts with simple steatosis, develops to non-alcoholic steatohepatitis (NASH), then cirrhosis, and if not controlled, eventually can develop to fibrosis and even hepatocellular carcinoma (HCC). The disease is linked to obesity, insulin resistance, and type 2 diabetes mellitus (T2DM), thus addressing these interconnected disorders could be an effective approach for its management. This review gives an overview the most recent relevant research studies and the on-going therapeutic options for NAFLD focusing on the recently discovered sodium glucose cotransporter 2 inhibitors (SGLT2i), the new antihyperglycemic class of drugs which recently gained adequate popularity, as well as their efficacy and applications in experimental and clinical work. | ||
Keywords | ||
Non-alcoholic fatty liver disease; Sodium glucose co-transporter 2 inhibitors, Insulin resistance, oxidative stress | ||
Statistics Article View: 273 PDF Download: 288 |